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Stable Coronary Artery Disease: 
When is Percutaneous Coronary 
Intervention Indicated?
Demosthenes G. Katritsis, MD
A B S T R A C T
In patients with chronic coronary artery disease (CAD) and good left ventricular 
function, percutaneous coronary intervention (PCI) does not confer any clear benefit 
in terms of hard long-term clinical outcomes, such as mortality, myocardial infarction 
or the need for subsequent revascularization, as compared with medical conservative 
treatment. Indeed, a meta-analysis of early data from 6 randomised controlled trials 
has showed convincingly that PCI improves anginal symptoms compared to conserva-
tive management, but there has been limited evidence on the effect of PCI on hard 
clinical outcomes. At the same time, the early fear of increased need for revascular-
ization after PCI is probably not warranted. By comparing the benefits against cost 
considerations, it seems that many percutaneous interventions that are currently per-
formed in patients with non-acute CAD are probably not justified.
I N T R O D U C T I O N
Significant coronary stenoses in patients with ischemic heart disease represent an 
established indication for revascularization. In longitudinal studies on patients with 
known or suspected coronary artery disease (CAD), positive thallium 201 studies pre-
dict a significantly higher overall mortality, cardiac death or myocardial infarction [1,2], 
whereas scintigraphy studies identify patients with a good prognosis at a low risk for 
future cardiac events [3]. However, the possible benefits and consequently indications 
of percutaneous coronary intervention (PCI) in the management of stable patients with 
CAD in non-acute settings have been debated for more than a decade. A meta-analysis 
of early data from 6 randomised controlled trials had showed convincingly that PCI 
improves anginal symptoms compared to conservative management [4], but there has 
been limited evidence on the effect of PCI on hard clinical outcomes, such as the risk 
of death, myocardial infarction (MI) and subsequent revascularization.
E V I D E N C E  F R O M  R A N D O M I Z E D  S T U D I E S
We have recently performed a meta-analysis of all randomized trials compar-
ing PCI to conservative treatment in patients with stable CAD. [5] We identified 
11 eligible randomized trials with pertinent data [6-20]. These were the Second 
Randomized Intervention Treatment of Angina (RITA2) trial, the Angioplasty 
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Compared to Medicine (ACME) study group with two sepa-
rately enrolled strata on single-vessel and two-vessel disease 
(designated here as ACME 1 and ACME 2, respectively), the 
Atorvastatin versus Revascularization Treatment (AVERT) 
trial, the Medicine, Angioplasty, or Surgery Study (MASS), 
and Medicine, Angioplasty, or Surgery Study II (MASS II) 
trial, a trial conducted by the Arbeitsgeneinschaft Leitende 
Kardiologische Krankenheusartzte (ALKK) group, and trials 
by Dakik et al, Sievers et al., Hambrecht et al., and Bech et 
al. Patient and disease characteristics are shown in Table 1. 
Mostly patients with single-vessel or two-vessel disease were 
included, but a considerable proportion of patients in MASS 
II had three-vessel disease. The large majority of patients had 
at least some anginal symptoms, but some trials included also a 
few patients without symptoms (Table 1). The reported average 
left ventricular ejection fraction was <60% in only one trial 
that lowered the eligibility threshold for ejection fraction to 
35% (mean 46%) [17].
R E S U L T S  O F  M E T A - A N A L Y S I S
A total of 2,950 patients were included in the meta-analysis 
(1,476 receiving PCI and 1,474 receiving conservative treat-
ment). There were a total of 196 deaths (PCI arm n=95 vs. 
conservative arm n=101), 235 patients had cardiac death or 
suffered an MI (PCI arm n=126 vs. conservative arm n=109), 
and 153 patients had non-fatal MIs (PCI arm n=87 vs. con-
servative arm n=66), while 215 patients underwent coronary 
artery bypass grafting (CABG) (PCI arm n=109 vs. conserva-
tive arm n=106) and 462 had PCI during follow-up (PCI arm 
n=219 vs. conservative arm n=243).
There was no significant difference between the two 
treatment strategies regarding mortality, cardiac death or 
MI, non fatal MI, and CABG or PCI during follow-up. By 
random effects, the risk ratios (95% confidence intervals) 
for the PCI vs. conservative treatment arms were 0.94 (0.72-
1.24), 1.17 (0.88-1.57), 1.28 (0.94-1.75), 1.03 (0.80-1.33), and 
1.23 (0.80-1.90), for these 5 outcomes, respectively (Table 2). 
The summary estimates showed no difference between PCI 
and conservative treatment in the mortality risk and the 95% 
confidence intervals clearly excluded relative risk differences 
of 28% (Figure 1a). If anything, there was a trend for more 
cardiac deaths or MIs, in particular non-fatal MIs (Figure 
1b), in patients who underwent PCI, with the point estimate 
suggesting approximately a 30% increase in the relative risk 
of non-fatal MI with PCI. A possible survival benefit was seen 
for PCI only in trials of patients who had a relatively recent MI 
(risk ratio 0.40, 95% confidence interval 0.17-0.95). Except for 
PCI during follow-up, there was no significant between-study 
heterogeneity for any outcome.
There was absolutely no difference in the need for CABG 
between the two compared treatment strategies (Table 2). 
The 95% confidence intervals also excluded differences in 
the relative risk exceeding 20% in favour of PCI and 33% in 
favour of conservative treatment. There was also no overall 
TABLE 1. Patient and Disease Characteristics in the Eligible Studies
Study Sample Age Male DM Prior MI No symptoms LVEF F/U
 MT/PCI mean (yrs) (%) (%) (%) (%) (%) (years)
RITA 2 514/504 58 median 82 9 47 20 ND* 7
ACME 1 115/112 60 100 18 31 9 68 2.4-5
ACME 2 50/51 60 100 18 41 18 67 2.4-5
AVERT 164/177 59 84 16 42 16 61 1.5
Dakik 22/19 53 59 ND 100 0 46 1
MASS 72/72 56 58 18 0 0 76 5
MASS II 203/205 60 68 30 41 ND 67 1
ALKK 151/149 58 87 16 100 0 ND† 4.7
Sievers 44/44 56 ND 0 55 ND ND 2
Hambrecht 51/50 61 100 23 46 0 63 1
Bech 91/90 61 64 12 25 0 65 2
CAD: coronary artery disease; DM: diabetes mellitus; EF: ejection fraction; F/U= follow-up; MI: myocardial infarction; MT: medical treatment; 
PCI: percutaneous coronary intervention; ND: no data available. See text for trial name abbreviations.
The ACME trial consists of two separately enrolled strata of patients with single-vessel (ACME 1) and two-vessel (ACME 2) disease.
*93% of the patients had very good or excellent wall motion score
Adapted from Katritsis et al [5].
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FIGURE 1. Comparison of percutaneous coronary intervention (PCI) vs. conservative medical treatment for (a) death, and (b) non-
fatal myocardial infarction. Each study is shown by its name along with the point estimate of the risk ratio and the respective 95% 
confidence intervals. In each panel, the size of the box denoting the point estimate in each study is proportional to the weight of 
the study. Also shown are the summary risk ratio and 95% confidence intervals according to the DerSimonian and Laird random 
effects model. [Adapted from Katritsis et al (reference 5)].
A                                                                                 B
TABLE 2. Summary Risk Ratios for Major Outcomes with PCI vs. Conservative Medical Treatment
Outcome RE Risk Ratio (95% CI) p-value FE Risk Ratio (95% CI) p-value
Death 0.94 (0.72-1.24) 0.68 0.95 (0.72-1.23) 0.68
Cardiac death or MI 1.17 (0.88-1.57) 0.28 1.16 (0.91-1.48) 0.24
Non-fatal MI 1.28 (0.94-1.75) 0.12 1.32 (0.97-1.79) 0.077
CABG 1.03 (0.80-1.33) 0.82 1.04 (0.81-1.34) 0.76
PCI 1.23 (0.80-1.90) 0.34 0.91 (0.77-1.07) 0.25
CABG: coronary artery bypass grafting; CI= confidence intervals; FE: fixed effects; MI: myocardial infarction; PCI: percutaneous coronary 
intervention; RE: random effects
Adapted from Katritsis et al [5].
difference in the risk for PCI during follow-up.
S U B G R O U P  A N A L Y S E S
D O C U M E N T E D  I S C H E M I A
Subgroup analyses (Table 3) produced no evidence that 
trials with definitive documentation of ischemia by exercise 
test and/or scintigraphy had different risk ratios compared 
with trials where functional ischemia was not as thoroughly 
documented (Table 3).
E F F E C T  O F  S T E N T S
The availability or not of stents also did not make any 
substantial difference for any of the 5 considered endpoints. 
Several of these trials were conducted in the time period before 
stents were routinely introduced in clinical practice. However, 
our meta-analysis found no evidence of superiority for the PCI 
strategy, even when analyses were limited to trials using stents. 
Finally, the impact of drug-eluting stents cannot be predicted, 
but the currently available data suggest that they may not offer 
any benefits besides reducing the need for revascularization, 
while the risk of death and MI is not affected [21].
R E C E N T  M Y O C A R D I A L  I N FA R C T I O N
The two trials that enrolled exclusively patients with 
relatively recent MI [17,18] showed a statistically significant 
reduction in the risk of death (p=0.037) and in the risk for 
subsequent PCI (p=0.029) and possibly also CABG (p=0.12) 
in the PCI arms. This subgroup differed significantly vs. the 
remaining trials for death and PCI risk ratios. Thus, PCI may 
actually be more effective in reducing the risk of death espe-
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cially in trials where all patients had a relatively recent MI. 
Longer follow-up and additional data would be useful before 
making a strong recommendation for using PCI in this setting, 
since data are driven largely by a single trial (ALKK).
P R O C E D U R E - R E L A T E D  M Y O C A R D I A L  
I N FA R C T I O N
We observed a trend for increased risk of MI in patients 
undergoing PCI. This may reflect also the risk carried by the 
invasive procedure per se. Data were not consistently available 
across these trials to separate procedure-related infarctions 
from subsequent MI. Additionally, micro-infarcts caused in a 
considerable proportion of patients undergoing PCI may have 
adverse prognostic importance in the long-term [22].
C O R O N A R Y  A R T E R Y  B Y PA S S  G R A F T I N G
The early literature suggested that PCI may cause an 
increased need for CABG [4]. We found no evidence for any 
increased need of CABG in the PCI strategy as compared 
with the conservative strategy.
I N T E N S E  M E D I C A L  T H E R A P Y
The included trials did not routinely use the full spectrum 
of conservative interventions currently available for CAD 
management. Interestingly, excellent results for the conser-
vative arm were obtained in a trial where special emphasis 
was placed on exercise, although it should be acknowledged 
that weekly counselling was also provided to patients in the 
exercise group [19]. Exercise may be unjustifiably under-uti-
lized in current clinical practice [23]. Moreover, the advent of 
statins has improved the treatment and outcomes of patients 
with chronic CAD with or without significant hypercholes-
terolemia [24]. This potential benefit was not available in any 
of the early trials. In view of current recommendations the 
angioplasty-treated group in the AVERT trial had inadequate 
control of their lipids. Overall, the different and potentially 
suboptimal medical management across the discussed trials is 
a limitation for unequivocal conclusions. However, one would 
expect even better outcomes, if medical management were 
indeed optimized.
C O N C L U S I O N S
In patients with chronic coronary artery disease and good 
left ventricular function, PCI does not confer any clear benefit 
in terms of hard long-term clinical outcomes, such as mortality, 
myocardial infarction or the need for subsequent revascular-
ization, as compared with medical conservative treatment. 
Evidence-based indications of PCI in this setting include relief 
of symptoms and recent myocardial infarction. At the same 
time, the early fear of increased need for revascularization 
after PCI is probably not warranted. By comparing the benefits 
against cost considerations, it seems that many percutaneous 
TABLE 3. Random Effects Risk Ratios (95% Confidence Intervals) for PCI vs. Conservative Medical Management in 
Subgroup Analyses
Subgroups  Death Cardiac death or MI Non-fatal MI CABG PCI
Stent availability 
 Yes 0.89 1.28 1.32 0.99 1.42
  (0.33-2.36) (0.66-2.48)†  (0.81-2.15) (0.35-2.77) (0.67-3.00)
 No 0.99 1.18 1.26 1.06 1.11
  (0.71-1.39) (0.85-1.63) (0.84-1.89) (0.80-1.40) (0.64-1.94)
All patients with recent M*
 Yes 0.40 1.01 1.26 0.24 0.42
  (0.17-0.95) (0.18-5.60) (0.27-5.83) (0.04-1.42) (0.20-0.91)
 No 1.04 1.31 1.35 1.06 1.41
  (0.78-1.39) (1.00-1.73) (0.96-1.90) (0.82-1.38) (0.88-2.24)
Ischemia documented in >80%†
 Yes 0.98 1.50 1.13 1.11 1.85
  (0.63-1.55) (0.88-2.56) (0.60-2.14) (0.64-1.90) (0.87-3.91)
 No 0.86 1.10 1.33 1.00 0.96
  (0.42-1.74) (0.71-1.72) (0.93-1.91) (0.58-1.72) (0.56-1.65)
CABG: coronary artery bypass grafting; MI: myocardial infarction; PCI: percutaneous coronary intervention.
* 8 days to 3 months prior to entry to the trial
† based on exercise test with or without scintigraphy
Adapted from Katritsis et al [5].
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interventions that are currently performed in patients with 
non-acute CAD are probably not justified.
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